Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Type 2 Diabetes

Clinical and regulatory intelligence for Type 2 Diabetes with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
10
Catalysts
0
Assets
7

Relevant assets

Clinical →
Digital →
Edinburgh →
Foundayo →
GI →
Laser →
UBT251 →

Relevant companies

Eli Lilly →
Novo Nordisk →

Recent signals(10)

ClinicalJuly 27, 2026

Laser Acupuncture Trial for Improving Body Shape in Women with Type 2 Diabetes

A clinical trial is assessing the effectiveness of laser acupuncture on body shape and health in women with uncontrolled Type 2 Diabetes.

ClinicalJuly 22, 2026

Study on Ethnic Differences in Adipose Tissue Dysfunction and Type 2 Diabetes Risk

A pilot study investigates ethnic differences in adipose tissue dysfunction and its role in insulin resistance and T2D.

CompetitiveJuly 20, 2026

GI Windows, Inc. Initiates Study on Duodenum to Ileal Diversion for Type 2 Diabetes

A clinical trial is underway to evaluate the efficacy of duodenum to ileal diversion in treating Type 2 Diabetes by monitoring HbA1c changes.

ClinicalJuly 6, 2026

Type 2 Diabetes Remission in Gynecologic Oncology Patients Post-Weight Loss Protocol

The study reviews T2D remission and glycaemic improvement in gynecologic oncology patients with class 3 obesity after a preoperative weight loss protocol.

ClinicalJune 29, 2026

Novo Nordisk Tests UBT251 for Type 2 Diabetes in New Clinical Trial

Novo Nordisk is conducting a clinical trial to evaluate the efficacy and safety of UBT251 in patients with type 2 diabetes.

ClinicalJune 26, 2026

Digital Health Tools Show Promise in Accelerating Lifestyle Habit Formation for Diabetes Risk

A randomized controlled trial is assessing the effectiveness of a digital intervention in accelerating healthy habit formation in adults at risk for Type 2 Diabetes.

ClinicalJune 21, 2026

Clinical Trial on Anti-inflammatory Diet's Impact on Type 2 Diabetes Management

A randomized controlled trial is evaluating the effects of an anti-inflammatory dietary intervention on inflammation and glycemic control in patients with type 2 diabetes.

ClinicalJune 19, 2026

Edinburgh Study Investigates Pancreas Lipotoxicity and Weight Loss in Type 2 Diabetes

The Edinburgh Diabetes Remission Study aims to explore the role of fat accumulation in the pancreas and its impact on type 2 diabetes remission through weight loss.

CompetitiveJune 16, 2026

Lilly's Foundayo shows superior results in Phase 3 trial for type 2 diabetes

Phase 3 ACHIEVE results indicate Foundayo outperformed oral semaglutide and dapagliflozin in treating type 2 diabetes.

ClinicalJune 10, 2026

AI-Driven Nutrition Study for Type 2 Diabetes Shows Promise for Glycemic Control

The AIM-MET study is evaluating a microbiome-targeted nutritional product's effect on glycemic control in type 2 diabetes over 24 weeks.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Endocrinology →
Type 2 Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.